Meta’s AI in Advertising Sparks Controversy
Meta faces scrutiny over AI's role in ad services amid concerns of illicit content on its platforms.
- Latest
- Trending
Meta faces scrutiny over AI's role in ad services amid concerns of illicit content on its platforms.
Revolutionary solvent-based method removes 98% of nanoplastics from water, promising cleaner oceans and safer ecosystems.
Roman Sterlingov contests his 30-year sentence, arguing that penalties exceed those in similar cases due to cumulative enhancements.
Explainable AI offers transparency in AI-driven drug discovery, providing insights into antibiotic development.
Biotech sees stable funding as 2024 venture capital and IPOs rise. Investors focus on late-stage assets amid economic challenges.
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
Cassava Sciences stands out as a leading debt-free stock with significant upside potential, offering strong financial health.
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.